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Down Syndrome (DS) is a genetic disorder that affects ~1 in 700 live births, caused by trisomy of human 
chromosome 21 (Hsa21), and results in cognitive impairment, craniofacial abnormalities, low muscle 
tone, and skeletal deficiencies. To study these phenotypes, we utilized the Ts65Dn mouse model, which 
contains three copies of approximately half the orthologous found on Hsa21 and exhibits similar 
phenotypes as found in humans with DS. Individuals with DS and Ts65Dn mice have deficits in bone 
mineral density (BMD), architecture, and bone strength. Over-expression of DYRK1A, a serine-threonine 
kinase encoded on Hsa21, has been linked to deficiencies in DS bone homeostasis. Epigallocatechin-3-
gallate (EGCG), an aromatic polyphenol found in high concentrations in green tea, is a known inhibitor of 
Dyrk1a activity. Normalization of Dyrk1a activity by EGCG may have the potential to regulate bone 
homeostasis and increase BMD and bone strength in individuals with DS. In this study, we hypothesized 
that EGCG obtained from different sources would have differential effects in correcting bone deficits 
associated with DS. To test our hypothesis, we performed Liquid chromatography–mass 
spectrometry (LC-MS) on EGCG and related compounds from different sources. The LC-MS analysis 
determined the amount of EGCG and the degradation in our stock solution. Next, we treated three-week-
old Ts65Dn and control male mice with EGCG for three weeks. At six weeks of age, mice were 
sacrificed. DXA and micro CT analysis were performed on the femurs and skulls of the mice to assess 
trabecular and cortical bone structure and BMD. Our results indicate the ability of EGCG to ameliorate 
skeletal deficiencies and compared pure EGCG with EGCG purchased from commercial vendors in 
correcting skeletal deficits associated with DS.  
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